Key result
Low-molecular-weight heparin compared with aspirin for total hip arthroplasty yielded costs per QALY gained of $315,000 at age 55 and $1.4 million at age 70, making aspirin more cost-effective.
Why the study?
Does low-molecular-weight heparin improve cost-effectiveness compared to aspirin for venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty?
Does low-molecular-weight heparin improve cost-effectiveness compared to aspirin for venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty?
Aspirin is a cost-effective choice for VTE prophylaxis following total hip arthroplasty, whereas the cost-effectiveness of LMWH following total knee arthroplasty depends on patient age.
No takes yet. Share an insight, caveat, or question.
Supports aspirin preference for cost-effective THA VTE prophylaxis; leaves open TKA age effects and prospective validation.
Schousboe et al. (2013) studied Venous thromboembolism after total joint arthroplasty. Low-molecular-weight heparin vs. Aspirin (160 mg) was evaluated on Costs per quality-adjusted life-year (QALY) gained. Low-molecular-weight heparin compared with aspirin for total hip arthroplasty yielded costs per QALY gained of $315,000 at age 55 and $1.4 million at age 70, making aspirin more cost-effective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: